These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 69034)

  • 1. Effect of busulfan on oncornavirus-like activity in platelets and chromosomes in polycythemia vera and essential thrombocythemia.
    Brodsky I; Fuscaldo AA; Erlick BJ; Fuscaldo KE
    J Natl Cancer Inst; 1977 Jul; 59(1):61-7. PubMed ID: 69034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of platelets and virus-like particles by busulfan in myeloproliferative disorders.
    Fuscaldo AA; Erlick BJ; Brodsky I; Fuscaldo KE
    Leuk Res; 1980; 4(1):105-17. PubMed ID: 6157962
    [No Abstract]   [Full Text] [Related]  

  • 3. A hitherto undescribed defect of platelet coagulant activity in polycythaemia vera and essential thrombocythaemia.
    Semeraro N; Cortellazzo S; Colucci M; Barbui T
    Thromb Res; 1979; 16(5-6):795-802. PubMed ID: 524321
    [No Abstract]   [Full Text] [Related]  

  • 4. Busulphan: effect on platelet RNA dependent DNA polymerase--implications in the treatment of polycythemia vera, thrombosis and atherosclerosis.
    Brodsky I
    Biomed Pharmacother; 1982; 36(3):125-7. PubMed ID: 6185158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of platelets from patients with thrombocythemia for reverse transcriptase and virus-like particles.
    Brodsky I; Fuscaldo AA; Erlick BJ; Kingsbury EW; Schultz GM; Fuscaldo KE
    J Natl Cancer Inst; 1975 Nov; 55(5):1069-74. PubMed ID: 54432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythroleukemia-like syndrome due to busulfan toxicity in polycythemia vera.
    Pezzimenti JF; Kim HC; Lindenbaum J
    Cancer; 1976 Dec; 38(6):2242-6. PubMed ID: 1069602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia.
    Michiels JJ; Berneman Z; Schroyens W; van Urk H
    Ann Hematol; 2003 Mar; 82(3):153-9. PubMed ID: 12634947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uracil mustard in the treatment of thrombocythemia.
    Robertson JH
    Blood; 1970 Mar; 35(3):288-97. PubMed ID: 5265825
    [No Abstract]   [Full Text] [Related]  

  • 9. Characteristic changes in platelet-large cell ratio, lactate dehydrogenase and C-reactive protein in thrombocytosis-related diseases.
    Kabutomori O; Kanakura Y; Iwatani Y
    Acta Haematol; 2007; 118(2):84-7. PubMed ID: 17622783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet production rate in polycythemia vera after myelosuppressive therapy.
    Kutti J
    Acta Med Scand; 1972 Sep; 192(3):161-4. PubMed ID: 5055260
    [No Abstract]   [Full Text] [Related]  

  • 11. Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis.
    Törnebohm-Roche E; Merup M; Lockner D; Paul C
    Am J Hematol; 1995 Mar; 48(3):163-7. PubMed ID: 7864024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of retrovirus in patients with myeloproliferative disease.
    Boyd MT; Maclean N; Oscier DG
    Lancet; 1989 Apr; 1(8642):814-7. PubMed ID: 2468065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycythaemia vera: differential diagnosis by ferrokinetic studies and treatment with busulphan (Myleran).
    Brodsky I; Kahn SB; Brady LW
    Br J Haematol; 1968 Apr; 14(4):351-61. PubMed ID: 5643288
    [No Abstract]   [Full Text] [Related]  

  • 14. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
    Spivak JL
    Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HEMORRHAGIC THROMBOCYTHEMIA AND THE "MYELOPROLIFERATIVE SYNDROME"].
    VON KNORRING
    Nord Med; 1964 Dec; 72():1443-6. PubMed ID: 14211013
    [No Abstract]   [Full Text] [Related]  

  • 16. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
    Gilbert HS
    Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
    Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
    Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of polycythemia vera with busulfan (myleran). Report on results in 40 patients].
    Urasiński I; Mysik M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1970; 94(4):360-6. PubMed ID: 4101127
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera].
    Nagai M; Tasaka T; Kamano H; Ohnishi H; Taoka T; Ikeda K; Kubota Y; Tanaka T; Irino S
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3267-70. PubMed ID: 3196045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.